OnKure Therapeutics, Inc. (OKUR) stock
OKURNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.82+0.24 (+9.30%)
Close on Nov 18, 2026Market cap $114.20MP/E –Yield –
OnKure Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
OnKure Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$62.14M. For fiscal 2025 it was -$62.95M. The highest annual figure on record is -$19.55M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$62.95M | – |
| FY2024 | Dec 31, 2024 | -$54.39M | – |
| FY2023 | Dec 31, 2023 | -$36.93M | – |
| FY2022 | Dec 31, 2022 | -$53.85M | – |
| FY2021 | Dec 31, 2021 | -$39.82M | – |
| FY2020 | Dec 31, 2020 | -$19.55M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$16.90M | – |
| Q1 FY2026 | Mar 31, 2026 | -$15.62M | – |
| Q4 FY2025 | Dec 31, 2025 | -$14.13M | – |
| Q3 FY2025 | Sep 30, 2025 | -$15.50M | – |
| Q2 FY2025 | Jun 30, 2025 | -$16.32M | – |
| Q1 FY2025 | Mar 31, 2025 | -$17.00M | – |
| Q4 FY2024 | Dec 31, 2024 | -$18.70M | -188.6% |
| Q3 FY2024 | Sep 30, 2024 | -$11.51M | – |
| Q2 FY2024 | Jun 30, 2024 | -$14.34M | – |
| Q1 FY2024 | Mar 31, 2024 | -$9.83M | – |
| Q4 FY2023 | Dec 31, 2023 | $21.11M | – |
| Q3 FY2023 | Sep 30, 2023 | -$20.89M | – |
| Q2 FY2023 | Jun 30, 2023 | -$21.04M | – |
| Q1 FY2023 | Mar 31, 2023 | -$16.12M | – |
| Q4 FY2022 | Dec 31, 2022 | -$14.56M | – |
| Q3 FY2022 | Sep 30, 2022 | -$13.84M | – |
| Q2 FY2022 | Jun 30, 2022 | -$12.43M | – |
| Q1 FY2022 | Mar 31, 2022 | -$13.02M | – |
| Q4 FY2021 | Dec 31, 2021 | -$10.62M | – |
| Q3 FY2021 | Sep 30, 2021 | -$12.75M | – |
| Q2 FY2021 | Jun 30, 2021 | -$9.23M | – |
| Q1 FY2021 | Mar 31, 2021 | -$7.21M | – |
| Q4 FY2020 | Dec 31, 2020 | -$6.25M | – |
| Q3 FY2020 | Sep 30, 2020 | -$5.10M | – |
| Q2 FY2020 | Jun 30, 2020 | -$3.70M | – |
| Q1 FY2020 | Mar 31, 2020 | -$4.50M | – |
See a number that looks wrong?